Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Immunotherapy for glioblastoma: quo vadis?

Weller M, Le Rhun E.

Nat Rev Clin Oncol. 2019 Mar 13. doi: 10.1038/s41571-019-0195-3. [Epub ahead of print] No abstract available.

PMID:
30867572
2.

Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?

Kurz SC, Wen PY.

Curr Treat Options Neurol. 2018 Apr 18;20(5):14. doi: 10.1007/s11940-018-0499-0. Review.

PMID:
29666934
3.

Antigen specific immunotherapy: Quo vadis?

Nestle FO.

Swiss Med Wkly. 2005 Apr 16;135(15-16):211. No abstract available.

PMID:
15971112
4.

Vaccines. Quo vadis?

Peshkin MM.

J Asthma Res. 1972 Mar;9(3):111-2. No abstract available.

PMID:
5075858
5.

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A.

Cancer Immunol Immunother. 2008 Mar;57(3):285-8. Epub 2007 Aug 25. No abstract available.

6.

Biochemotherapy in metastatic melanoma: quo vadis?

Queirolo P, Acquati M.

Melanoma Res. 2005 Oct;15(5):471-3. No abstract available.

PMID:
16179877
7.

Angiogenesis inhibition: quo vadis?

Weller M.

Neuro Oncol. 2012 Nov;14(11):1315. doi: 10.1093/neuonc/nos274. No abstract available.

8.

Immunotherapy for brain tumors: quo vadis?

Lesniak MS.

Expert Rev Neurother. 2006 Apr;6(4):447-51. No abstract available.

PMID:
16623643
9.

Quo Vadis medycyno regeneracyjna?: Quo Vadis Regenerative Medicine?

Ratajczak MZ, Suszyńska M.

Acta Haematol Pol. 2013 Jul;44(3):161-170.

10.

Alzheimer's amyloid immunotherapy: quo vadis?

Gandy S, Heppner FL.

Lancet Neurol. 2005 Aug;4(8):452-3. Review. No abstract available.

PMID:
16033686
11.

Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology.

Kimball AB, Kupper TS.

Clin Dermatol. 2008 Sep-Oct;26(5):554-61. doi: 10.1016/j.clindermatol.2007.11.007. Review.

PMID:
18755375
12.

Endothelial (DYS)Function: Quo vadis, Cur vadis.

O'Rourke MF.

J Hypertens. 2012 Jul;30(7):1321-4. doi: 10.1097/HJH.0b013e32835522e2. No abstract available.

PMID:
22706391
13.

Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets?

Lefranc F, Le Rhun E, Kiss R, Weller M.

Cancer Treat Rev. 2018 Jul;68:145-154. doi: 10.1016/j.ctrv.2018.06.017. Epub 2018 Jun 26. Review.

14.

Meningioma research-status quo and quo vadis.

Preusser M, Brastianos P, Shih HA.

Chin Clin Oncol. 2017 Jul;6(Suppl 1):S1. doi: 10.21037/cco.2017.06.21. No abstract available.

15.

Quo venis quo vadis: the evolution of arthroscopy.

Jackson RW.

Arthroscopy. 1999 Sep;15(6):680-5. No abstract available.

PMID:
10495192
16.

Cancer. Quo vadis, specificity?

Schreiber H, Rowley DA.

Science. 2008 Jan 11;319(5860):164-5. doi: 10.1126/science.1153713. No abstract available.

PMID:
18187644
17.

DGGG Guidelines Programme: Status Quo - Quo Vadis!

Beckmann MW, Linde I, Bütof C, Kreienberg R, Gass P.

Geburtshilfe Frauenheilkd. 2014 Mar;74(3):251-259.

18.

Quo vadis nanomedicine?

Luxenhofer R, Barz M, Schillmeier M.

Nanomedicine (Lond). 2014 Jul;9(14):2083-6. doi: 10.2217/nnm.14.140.

19.

Disclosure of potential conflicts of interest in dermatological guidelines in Germany - an analysis - status quo and quo vadis.

Rosumeck S, Sporbeck B, Rzany B, Nast A.

J Dtsch Dermatol Ges. 2011 Apr;9(4):297-304. doi: 10.1111/j.1610-0387.2011.07615.x. English, German.

PMID:
21439013
20.

Quo vadis?

Wilson TG.

Quintessence Int. 2004 Sep;35(8):597. No abstract available.

PMID:
15366520

Supplemental Content

Support Center